Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial

Background: Myocardial fibrosis leads to ventricular dysfunction and worsened prognosis, especially after ST-segment elevation myocardial infarction (STEMI). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) offer cardiovascular benefits by reducing markers of myocardial fibrosis and fibroblast ac...

Descripción completa

Detalles Bibliográficos
Autores: Ortega-Paz, L, Laudani, C, Sionis, A, Vidal-Cales, P, Arevalos, V, Andrea, R, Morr, CI, De Diego, O, Ortega, E, Jimenez-Trinidad, FR, Dantas, AP, Angiolillo, DJ, Sabaté, M, Ortiz-Pérez, JT, Brugaletta, S
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p19758
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19758
Access Level:acceso abierto
Palabra clave:dapagliflozin
myocardial fibrosis
ventricular function
left
myocardial infarction
sodium-glucose transporter 2 inhibitors
cardiac magnetic resonance
randomized controlled trial
ventricular remodeling
heart failure
extracellular space
id ES_eeaa7a9d61b5fc9ddd89d5bd4ee4617e
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p19758
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI TrialOrtega-Paz, LLaudani, CSionis, AVidal-Cales, PArevalos, VAndrea, RMorr, CIDe Diego, OOrtega, EJimenez-Trinidad, FRDantas, APAngiolillo, DJSabaté, MOrtiz-Pérez, JTBrugaletta, Sdapagliflozinmyocardial fibrosisventricular functionleftmyocardial infarctionsodium-glucose transporter 2 inhibitorscardiac magnetic resonancerandomized controlled trialventricular remodelingheart failureextracellular spaceBackground: Myocardial fibrosis leads to ventricular dysfunction and worsened prognosis, especially after ST-segment elevation myocardial infarction (STEMI). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) offer cardiovascular benefits by reducing markers of myocardial fibrosis and fibroblast activity. However, the effects of SGLT2i on myocardial fibrosis deposition among STEMI patients undergoing primary percutaneous coronary intervention (PCI) have not yet been evaluated. Study and Design: The effect of DAPAgliflozin on myocardial fibrosis and ventricular function in patients with STEMI (DAPA-STEMI) trial is a phase III, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the effects of dapagliflozin on myocardial fibrosis and ventricular function, evaluated using cardiac magnetic resonance (CMR), in STEMI patients undergoing primary PCI. Eligible patients were 30 to 85 years old and exhibited a left ventricular ejection fraction <= 50%. A total of 120 patients with STEMI were expected to be randomized 1:1 to receive dapagliflozin 10 mg or placebo daily for six months. The primary endpoint is the change in the extracellular volume fraction of the remote myocardium from baseline to six months, as measured by CMR. The secondary endpoints include changes in the circulating C-terminal propeptide of type I procollagen, N-terminal propeptide of type III procollagen, and Galectin-3 from baseline to six months. The study was stopped prematurely due to slow recruitment, with 54 enrolled patients, limiting the statistical power to detect changes in the primary endpoint between groups. Conclusions: The DAPA-STEMI trial will provide insights into the impact of dapagliflozin on myocardial fibrosis and ventricular remodeling in patients with STEMI undergoing primary PCI.MDPI2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19758Journal of Cardiovascular Development and DiseaseISSN: 23083425reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p197582026-06-14T12:41:47Z
dc.title.none.fl_str_mv Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
title Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
spellingShingle Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
Ortega-Paz, L
dapagliflozin
myocardial fibrosis
ventricular function
left
myocardial infarction
sodium-glucose transporter 2 inhibitors
cardiac magnetic resonance
randomized controlled trial
ventricular remodeling
heart failure
extracellular space
title_short Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
title_full Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
title_fullStr Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
title_full_unstemmed Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
title_sort Effect of DAPAgliflozin on Myocardial Fibrosis and Ventricular Function in Patients with ST-Segment Elevation Myocardial Infarction-DAPA-STEMI Trial
dc.creator.none.fl_str_mv Ortega-Paz, L
Laudani, C
Sionis, A
Vidal-Cales, P
Arevalos, V
Andrea, R
Morr, CI
De Diego, O
Ortega, E
Jimenez-Trinidad, FR
Dantas, AP
Angiolillo, DJ
Sabaté, M
Ortiz-Pérez, JT
Brugaletta, S
author Ortega-Paz, L
author_facet Ortega-Paz, L
Laudani, C
Sionis, A
Vidal-Cales, P
Arevalos, V
Andrea, R
Morr, CI
De Diego, O
Ortega, E
Jimenez-Trinidad, FR
Dantas, AP
Angiolillo, DJ
Sabaté, M
Ortiz-Pérez, JT
Brugaletta, S
author_role author
author2 Laudani, C
Sionis, A
Vidal-Cales, P
Arevalos, V
Andrea, R
Morr, CI
De Diego, O
Ortega, E
Jimenez-Trinidad, FR
Dantas, AP
Angiolillo, DJ
Sabaté, M
Ortiz-Pérez, JT
Brugaletta, S
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv dapagliflozin
myocardial fibrosis
ventricular function
left
myocardial infarction
sodium-glucose transporter 2 inhibitors
cardiac magnetic resonance
randomized controlled trial
ventricular remodeling
heart failure
extracellular space
topic dapagliflozin
myocardial fibrosis
ventricular function
left
myocardial infarction
sodium-glucose transporter 2 inhibitors
cardiac magnetic resonance
randomized controlled trial
ventricular remodeling
heart failure
extracellular space
description Background: Myocardial fibrosis leads to ventricular dysfunction and worsened prognosis, especially after ST-segment elevation myocardial infarction (STEMI). Sodium-glucose cotransporter 2 inhibitors (SGLT2is) offer cardiovascular benefits by reducing markers of myocardial fibrosis and fibroblast activity. However, the effects of SGLT2i on myocardial fibrosis deposition among STEMI patients undergoing primary percutaneous coronary intervention (PCI) have not yet been evaluated. Study and Design: The effect of DAPAgliflozin on myocardial fibrosis and ventricular function in patients with STEMI (DAPA-STEMI) trial is a phase III, multicenter, randomized, double-blind, placebo-controlled trial. The study aims to assess the effects of dapagliflozin on myocardial fibrosis and ventricular function, evaluated using cardiac magnetic resonance (CMR), in STEMI patients undergoing primary PCI. Eligible patients were 30 to 85 years old and exhibited a left ventricular ejection fraction <= 50%. A total of 120 patients with STEMI were expected to be randomized 1:1 to receive dapagliflozin 10 mg or placebo daily for six months. The primary endpoint is the change in the extracellular volume fraction of the remote myocardium from baseline to six months, as measured by CMR. The secondary endpoints include changes in the circulating C-terminal propeptide of type I procollagen, N-terminal propeptide of type III procollagen, and Galectin-3 from baseline to six months. The study was stopped prematurely due to slow recruitment, with 54 enrolled patients, limiting the statistical power to detect changes in the primary endpoint between groups. Conclusions: The DAPA-STEMI trial will provide insights into the impact of dapagliflozin on myocardial fibrosis and ventricular remodeling in patients with STEMI undergoing primary PCI.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19758
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19758
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Journal of Cardiovascular Development and Disease
ISSN: 23083425
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869423742345543680
score 15.81155

Similares en LA Referencia